Intra-Cellular Therapies, Inc. (ITCI)
| Previous close | 72.00 |
| Open | 72.36 |
| Bid | 73.23 x 100 |
| Ask | 73.62 x 100 |
| Day's range | 71.73 - 74.56 |
| 52-week range | 45.50 - 84.89 |
| Volume | |
| Avg. volume | 926,998 |
| Market cap | 7.167B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 90.04 |
GlobeNewswireIntra-Cellular Therapies Prices Public Offering of Common Stock
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share. All of the shares in the offering will be sold by Intra-Cellular Ther
Investor's Business DailyBiotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point
Intra-Cellular stock: Shares rocketed more than 23% Tuesday, sending them past their latest buy point on the stock market today.
ZacksIntra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
